Adenovirus early gene 1A (E1A) possesses a potent transcriptional repression function within the first 80 amino acids (E1A 1-80). Our previous analysis of subdomain 1 (residues 1 to 30) revealed strong correlations between residues required for repression and for disruption of TBP-TATA complexes. Here, we report a functional analysis of subdomain 2 (48 to 60) by alanine-scanning mutagenesis. 53Ala, 54Pro, 55Glu, and 56Asp are required for repression in vitro and in vivo and for efficient interaction with p300 but not for disruption of TBP-TATA. These combined results suggest a model for E1A transcription repression. E1A through subdomains 1 and 2 uses coactivators like p300 as scaffolds to access E1A repressible promoters. At the promoter, subdomain 1 interacts with TBP to disrupt TBP-TATA and abort transcription initiation. In further support of this model, we show that E1A 1-80 bound to the p300-binding site retains the ability to interact with TBP.
Introduction
Early region 1A (E1A) is the first viral transcription unit expressed following infection by human adenovirus (Ad). E1A encodes two multifunctional regulatory oncoproteins of 243-and 289-amino-acid residues, referred to as 243R and 289R (Fig. 1A) which interact with a number of cellular transcription regulatory factors. E1A 243R and 289R are complex multifunctional proteins whose expression can result in diverse functions which include transcriptional activation, transcriptional repression, induction of cellular DNA synthesis, cell immortalization, cell transformation, and interestingly the inhibition of tumorigenesis and metastasis. E1A 243R shares the identical amino acid sequence with E1A 289R except for conserved region 3 (CR3), a 46-amino-acid domain unique to 289R. Using synthetic polypeptides, our laboratory was able to demonstrate that CR3 is an independent functional domain that is both essential and sufficient for activation of viral early genes (Green et al., 1988; Lillie et al., 1987) . CR1 (amino acids 40 to 80) and CR2 (amino acids 120 to 139) are common to both 243R and 289R and together with the non-conserved N terminus (amino acids 1 to 39) are required for the growth regulatory functions of E1A (Moran, 1993; Moran et al., 1986) . Conserved region 4 (CR4) is localized within a 14-amino-acid region near the C terminus of exon 2 and possesses an independent transformation suppression activity (Subramanian et al., 1989; Boyd et al., 1993) .
E1A 243R induces cell cycle progression of quiescent cells apparently by two pathways (Lillie et al., 1987; Howe et al., 1990 ) that may act synergistically (Shenk, 2001 ). The first and most studied pathway involves interaction of the retinoblastoma tumor suppressor protein (pRb) with sequences within CR1 and CR2. The second pathway leading to cell cycle progression maps within the E1A N-terminal 80 amino acids (Song et al., 1995a) . Cellular DNA induction, cell immortalization, and oncogene cooperation have been shown by genetic studies to require this N-terminal pathway. An interesting biological function of E1A, the ability to repress transcription from genes involved in growth regulation, maps to sequences within CR1 and the E1A N-terminus (Boulukos and Ziff, 1993; Hen et al., 1985; Stein and Ziff, 1987; Webster et al., 1988; Yu et al., 1990) .
The multifunctional protein domain structure of E1A complicates the investigation of a single functional domain in Virology 351 (2006) 312 -321 www.elsevier.com/locate/yviro the context of the full-length molecule. To investigate the mechanism of E1A transcription repression, our laboratory developed in vitro transcription and in vivo cell microinjection assays to analyze transcriptional repression Loewenstein et al., 1998; Song et al., 1995a Song et al., , 1995b Song et al., , 1995c Song et al., , 1997 . Using these assays, a recombinant protein containing only the N-terminal 80 amino acids (E1A 1-80) was found to strongly repress transcription of E1A-repressible promoters in a manner that faithfully recapitulates the transcriptional repression activity of the full-length E1A 243R protein. Briefly, wildtype E1A 1-80 has the equivalent transcription repression activity as the full-length E1A 243R molecule in the in vitro transcription repression assay and in the in vivo cell microinjection assay (Song et al., 1995a) . Further, a series of deletion mutants constructed within an E1A 1-80 background (1-80Δ4-25, 1-80Δ26-35, 1-80Δ30-49, 1-80Δ48-60, 1-80Δ61-69, 1-80Δ70-80) were found to have the same transcription repression activities in vitro as reported for the corresponding full-length E1A 243R mutants (Howe et al., 1990; Song et al., 1995a) . Promoters reported to be repressible in vivo by the expression of E1A 243 are repressed in vitro by both E1A 1-80 and E1A 243R (human collagenase, rat insulin II, SV40 early promoter, and the HIV LTR promoter) (Song et al., 1995a (Song et al., , 1995b . E1A non-repressible promoters such as the adenovirus major late promoter (MLP), human histone 4 promoter, and the Rous sarcoma virus promoter are resistant to repression by both E1A 1-80 and E1A 243R proteins in vitro, attesting to the promoter specificity of repression by E1A 1-80. The basal transcription factor TBP (TATA-binding protein) has been strongly implicated as a functional target of E1A repression (Song et al., 1995a; 1995b , 1995c Boyd et al., 2002) . Briefly, repression by E1A 243R and E1A 1-80 in vitro is reversed by the addition of TFIID or recombinant TBP. Further, the addition of TBP to an E1A 1-80 affinity-depleted nuclear extract restores the ability of the extract to support transcription. Significantly, E1A 243R as well as E1A 1-80 interferes with TBP-TATA interaction in vitro. This ability of E1A to disrupt interaction between TBP and the TATA box is unique among transcriptional repressors that target TBP (Song et al., 1997) .
The multifunctional transcription factor p300 interacts with E1A through sequences important for the E1A transcription repression function. p300 and the closely related CREB-binding protein (CBP) (Chrivia et al., 1993; Eckner et al., 1994) belong to a conserved family of coactivators recruited to cellular promoters through interaction with specific transcription factors or as a complex with other cofactors (Arany et al., 1995; Chakravarti et al., 1996 Chakravarti et al., , 1999 Yang et al., 1996) . Genes coactivated by p300/CBP are potential targets for the E1A repression function because those genes are often involved in cell differentiation and for the maintenance of quiescence. E1A has been reported to possess several biochemical activities, some of which could be related to the E1A repression function, including inhibition of PCAF-dependent transcription (Yang et al., 1996; Puri et al., 1997) and blocking recruitment of RNA polymerase II on cyclic AMP-dependent promoters (Nakajima et al., 1997) . These findings are of great interest, but it is unclear to what extent they relate to the E1A transcription repression function.
To help understand E1A N-terminal activities and their in vivo significance, a structure-function analysis of E1A singleamino-acid substitution mutants of the first thirty amino acids of E1A's N-terminus has been carried out (Boyd et al., 2002) . Two regions of importance within subdomain 1 were found. First, amino acids 2Arg, 3His, 4Iso, 5Iso, and 6Cys are required for E1A repression as well as for the ability of E1A to disrupt a TBP-TATA complex. Second, amino acid 20Leu is essential for E1A repression and for disruption of a TBP-TATA complex. Of these critical amino acids, only 6Cys is essential for interaction with E1A's cellular partners TBP and p300 in an in vitro binding assay. These studies indicate that both p300 and TBP are cellular targets for E1A repression and led to a proposed model that the E1A repression domain uses p300 and/or similar interacting coactivators as molecular scaffolds to target specific promoters involved in growth regulation. As described here, to further explore this hypothesis, we constructed alaninescanning single amino acid substitution mutants within the second domain required for E1A repression, amino acids 48 to 60. The results of functional analysis of these mutants add further support to a two-step model for E1A transcriptional repression.
Results
Amino acid residues 53, 54, 55, and 56 within subdomain 2 are required for in vitro transcription repression
We have cloned, expressed, and characterized a panel of alanine-scanning mutants covering amino acids 48 to 60, the second subdomain required for the E1A N-terminal repression function. These mutants were constructed in an E1A 1-80 amino acid backbone which is sufficient for the E1A transcription repression function. The scanning mutants were cloned into the pQE70 expression vector from which C-terminal 6× His tagged polypeptides were expressed. Polypeptides were purified to near homogeneity (Fig. 1B) and used for in vitro and in vivo functional studies described below.
First examined was the ability of each E1A 1-80 single amino acid substitution mutant to repress transcription initiated in vitro using a well-characterized assay that measures transcription from the HIV LTR promoter and yields a run-off transcript of 874 bases . All mutants were examined by comparison to wild-type E1A 1-80 at 30 ng, 60 ng, 125 ng, and 250 ng of polypeptide per reaction mixture. In the absence of E1A 1-80, there is strong transcription from the HIV LTR (Fig. 2 , first reaction, top row). E1A 1-80 polypeptide represses transcription in a dose-dependent manner. At the lowest concentration, transcription is repressed over 60%, and at the highest concentration, transcription is repressed over 96%, as measured by PhosphorImage analysis. E1A 1-80Δ4-25, which deletes subdomain 1, does not significantly repress transcription. E1A 1-80Δ48-60, which deletes subdomain 2, is also substantially defective for repression function, as expected.
Four E1A 1-80 substitution mutants were found to be substantially defective: 53Ala→Gly, 54Pro→Ala, 55Glu→Ala, and 56Asp→Ala (Fig. 2 , second and third row). The other single amino acid substitution mutants within residues 48 to 60 were at or near wild-type activity as illustrated by 48Asp→Ala (Fig. 2, second row) . Independent preparations of His tagged E1A 1-80 53Gly, E1A 1-80 54Ala, E1A 1-80 55Ala, and E1A 1-80 56Ala were examined in the in vitro transcription assay with essentially the same results, confirming that the deficiency of the repression function was due to the amino acid substitution and not to variability in polypeptide preparation. We conclude that a "cluster" of amino acids between residues 53 and 56 is important for the E1A transcription repression function in vitro.
The amino acid residues required for in vitro transcription repression are the same as those required for transcription in vivo
It is important to establish that mutants identified as repression defective in the in vitro assay are also defective in vivo. For this purpose, a cell microinjection repression assay was employed Boyd et al., 2002) . E1A 1-80 mutant polypeptides are injected directly into the cell nucleus and repression of transcription from coinjected SV40 large T antigen promoter-reporter measured after 4 h by immunofluorescence using monoclonal antibody directed against the SV40 T antigen. This assay has an advantage relative to transient expression of not being influenced by differences in expression of mutant polypeptides in transfected cells.
T antigen (red fluorescence) is detected in about 80% of successfully injected cells that are scored by green fluorescent protein (GFP) expressed from coinjected pEGFRN-1 (Clontech) (Fig. 3A) . Coinjection of E1A 1-80 at 25 ng/μl represses transcription from the SV40 T antigen promoter over 90% (Fig.  3A) . However, no significant repression of the SV40 promoter was observed after coinjection with the repression-defective mutant E1A 1-80Δ48-60 (Fig. 3A) . When E1A 1-80 53Gly, E1A 1-80 54Ala, E1A 1-80 55Ala, and E1A 1-80 56Ala were coinjected at 25 ng/μl, their inability to efficiently repress transcription is apparent (Fig. 3B) . The other single amino acid substitution mutants within E1A 1-80 residues 48 to 60 exhibited wild-type or near wild-type repression ability as illustrated by E1A 1-80 48Ala (Fig. 3B ).
Quantitative comparison of the E1A 48 to 60 amino acid requirements for transcription repression in vitro and in vivo
The averages of 3 to 5 independent in vitro transcription repression analyses are shown in Fig. 4A , and the averages of 3 to 4 cell microinjection analyses are shown in Fig. 4B . In both analyses, E1A 1-80 53gly, E1A 1-80 54Ala, E1A 1-80 55Ala, and E1A 1-80 56Ala were substantially defective for transcription repression function. In the in vivo assay, the substitution of alanine for 51Val and 52Thr appears to produce a partially defective phenotype. It is possible that the in vivo assay is somewhat more stringent in measuring transcription repression, and that these amino acids are also involved in the repression function. In any case, it is clear that the core "group" of residues (53Ala, 54Pro, 55Glu, and 56Asp) is important for E1A 1-80 transcription repression function both in vitro and in vivo.
The amino acid residues in subdomain 2 important for E1A repression are needed to interact with p300 but not to bind TBP TBP and p300 have been implicated as cellular targets or partners in E1A repression. To determine whether single amino acid mutations in subdomain 2 affect the ability of E1A 1-80 to interact with TBP or the E1A-binding site in p300, proteinprotein-binding assays were performed. Fusion proteins containing (i) GST with full-length TBP (GST-TBP) and (ii) GST with a p300 fragment containing the E1A-binding site (GSTp300 segment B′) were immobilized on GSH-agarose and incubated with wild-type and mutant E1A 1-80 polypeptides. The input was monitored to ensure that approximately equal levels of E1A polypeptides were available for binding. E1A 1-80 polypeptides bound to the GST fusion proteins were resolved by SDS PAGE, transferred to PVDF membranes, and analyzed by immunoblot analysis using an affinity-purified polyclonal antibody raised against the E1A CR1 domain. Results from a typical binding experiment are presented in Fig.  5A . Wild-type E1A 1-80 bound efficiently to both GST-p300 and GST-TBP (Fig. 5A ) but not to GST alone (data not shown). These interactions are specific since the deletion mutant E1A 1-80Δ4-25 is substantially defective for binding to both GSTp300 and GST-TBP (Fig. 5A ). This mutant was previously shown to lack E1A repression activity and to lack the ability to bind TBP and p300 (Song et al., 1997; Boyd et al., 2002) . The deletion mutant E1A 1-80Δ48-60, which is also defective for transcription repression function, is also substantially defective in its ability to bind GST-p300 but is not significantly defective for binding GST-TBP. These findings indicate that there is no binding site for TBP within amino acids 48 to 60. Consistent with this finding, no single amino acid substitution mutant was defective in ability to bind TBP (Fig. 5A) . In contrast, the single amino acid substitution mutants E1A 1-80 53Gly, E1A 1-80 54Ala, E1A 1-80 55Ala, and E1A 1-80 56Ala were all significantly defective for binding GST-p300. Fig. 5B is a quantitative representation of 3 to 4 in vitro binding assays for GST-p300 segment B′. E1A 1-80 53Gly, E1A 1-80 54Ala, E1A 1-80 55Ala, and E1A 1-80 56Ala exhibited phenotypes that bound p300 less than 40% as effectively as wild-type E1A 1-80. Mutants with substitution of Ala for 50Asp, 51Val, and 52Thr also bound p300 less effectively than wild-type E1A 1-80, suggesting that these contiguous residues may also be involved in the interaction with p300. However, it is clear that 53Gly, 54Ala, 55Ala, and 56Ala, the "core" residues defective for transcription repression, are the most defective residues for p300 binding. Fig. 5C is a quantitative representation of three independent assays for the interaction of the single substitution mutants with GST-TBP. No single residue between 48 and 60 could be identified as important for interaction with GST-TBP. Further, E1A 1-80Δ48-60 exhibits a phenotype that is not substantially defective for interaction with GST-TBP, indicating that although amino acids in this region are important for the repression function and for interaction with p300 they are dispensable for interaction with TBP.
In vitro recruitment of TBP to a p300 E1A 1-80 complex To determine whether the E1A repression domain can interact with both p300 and TBP in a manner that could be functionally significant, we asked if E1A 1-80 could recruit TBP to a p300/E1A 1-80 complex. Fig. 6A shows a schematic of an in vitro binding assay that tests these interactions. Briefly, GST agarose or GST-p300 segment B′ agarose is incubated with an 0.5-to 20-fold molar excess of E1A 1-80 polypeptide. After removing unbound E1A 1-80, the resin is incubated with about a two fold molar excess of TBP. After removal of unbound TBP, bound proteins are eluted, resolved by SDS PAGE, and subjected to immunoblot analysis. Shown in Fig. 6B are samples probed with antibody against E1A and shown in Fig.  6C are aliquots of the same samples probed with antibody against TBP. Lanes 1 and 2 are from GST agarose incubated with 0. 5× and 20× molar excess of E1A 1-80. Neither bound detectable amounts of E1A 1-80 or TBP. Lane 3 is GST-p300 segment B′ agarose that was not preincubated with E1A 1-80 polypeptide and then incubated with TBP. No detectable TBP bound directly to GST-p300 segment B′. Samples shown in lanes 4 through 8 were preincubated with increasing amounts of E1A 1-80 and then challenged with TBP. Increasing amounts of bound E1A 1-80 were detected in the eluted samples, and importantly, increasing amounts of TBP were also found in these samples. These findings demonstrate that TBP can interact in a dose-dependent manner with the E1A N-terminus bound as a complex with the E1A-binding domain of p300.
Residues within the E1A 1-80 subdomain 2 are not needed to disrupt interaction between TBP and the TATA box
We have previously shown that the E1A 243R protein and the E1A 1-80 polypeptide can disrupt interaction between TBP and TATA box DNA, as shown by both DNase footprint analysis and EMSA (gel shift analysis) (Song et al., 1997; Boyd et al., 2002) . This ability implies an in vivo function for the E1A repression domain. It was therefore important to examine the E1A 1-80 mutant polypeptides for ability to interfere with TBP-TATA interaction. An end-labeled oligonucleotide probe containing a TATA element was incubated with recombinant TBP in the absence or presence of wild-type E1A 1-80 or mutant E1A 1-80 polypeptide. TBP-TATA complexes were resolved by gel electrophoresis on a low percentage acrylamide gel and visualized by PhosphorImage analysis. As shown in Fig. 7 , when TBP is incubated in a reaction mixture containing the consensus TATA element oligonucleotide, a shifted band containing the TBP-TATA complex is formed. Addition of wildtype E1A 1-80 polypeptide disrupts the formation of the TBP-TATA complex in a dose-dependent manner (30 ng, 60 ng, and (EMSA) showing that residues within the E1A 1-80 subdomain 2 are dispensable for disruption of a TATA-TBP complex. GST-TBP was incubated with a radiolabeled TATA consensus oligonucleotide in the presence or absence of E1A 1-80 polypeptides. In the presence of GST-TBP, a strong gel shift is detected. E1A 1-80 disrupts the TBP/TATA complex in a dose-dependent manner, whereas E1A 1-80Δ4-25 which lacks E1A 1-80 subdomain 1 loses the ability to disrupt a TATA/TBP gel shift. By contrast, E1A 1-80Δ48-60, which lacks subdomain 2, retains the ability to disrupt a TATA/TBP gel shift. 120 ng per reaction). The deletion mutant E1A 1-80Δ48-60 clearly exhibits a wild-type phenotype in that it is able to disrupt the TBP-TATA interaction in a dose-dependent manner. However, E1A 1-80Δ4-25, the deletion mutant lacking repression subdomain 1, has no effect on TBP-TATA complex formation, as previously reported (Boyd et al., 2002) . Analysis of single amino acid substitution mutants, both wild type and defective for transcription repression, found no mutant unable to disrupt a TBP-TATA complex (data not shown).
Discussion
Reported here are the results of mutational analysis of subdomain 2 (residues 48-60) of the E1A 1-80 repression domain. Table 1 summaries the findings from the mutational analysis of both subdomains needed for the repression function of E1A 1-80. As observed for subdomain 1 (Boyd et al., 2002) , there is good agreement among the amino acids critical for the repression function in vitro and in vivo. Residues 53Ala, 54Pro, 55Glu, and 56Asp are important for function because when these residues are substituted with alanine (glycine for 53Ala), the resultant phenotype is substantially defective for transcription repression function. Unlike the defective mutants within subdomain 1, the mutants defective for transcription repression retain the ability to disrupt TBP-TATA interaction. Consistent with this finding, 53Gly, 54Ala, 55Ala, and 56Ala are not defective for interaction with TBP. These mutants are, however, significantly deficient for interaction with p300, which may explain the deficiency of 53Gly, 54Ala, 55Ala, and 56Ala for transcription repression. p300 was first identified by its interaction with E1A and appears to play an important role in the ability of E1A to repress transcription. But as discussed in the introduction, the nature of this role is unclear. Of interest in this regard, several amino acid substitution mutants (in 50Asp, 51Val, and 52Thr-see Fig. 5A ) adjacent to the critical core residues 53Ala, 54Pro, 55Glu, and 56Asp, exhibited reduced affinity for p300. It is possible that these amino acids are involved in p300 interaction but are not sufficiently deficient to exhibit a defective repression phenotype in vitro. It is noted that 50Asp, 51Val, and 52Thr do exhibit reduced transcription repression ability in vivo.
In previous studies, we identified a component of the basal transcription machinery, TBP, as a key target of the E1A repression function. Because p300 appears to be involved in E1A repression and because p300 functions as a coactivator for promoters that regulate the cell cycle and cell differentiation, it is an attractive possibility that promoter-bound p300 serves as a binding site that E1A utilizes to gain access to specific cellular promoters involved in growth regulation. These considerations and the observations from mutational analysis of the two subdomains within the N-terminal repression domain suggest a two-step model.
During the first step, E1A uses p300 as a high-affinity "molecular scaffold" to access specific E1A repressible promoters. E1A likely binds p300 through 6Cys (and possibly adjacent amino acids) within the first subdomain and with 53Ala, 54Pro, 55Glu, and 56Asp (and possibly adjacent amino acids) within the second subdomain. In addition to p300, the E1A N-terminal repression domain may target other coactivators as scaffolds, including CBP, PCAF, GCN5, p400, and the TRRAP chromatin remodeling complex which have been reported to bind the E1A N-terminus (for review, see Frisch and Mymryk, 2002) .
During the second step, after gaining access to the promoter through interaction with a "molecular scaffold", the N-terminal subdomain of E1A is able to interact with TBP. This interaction may alter the conformation of TBP, thus melting it from the TATA box. The in vitro TBP recruitment assay presented here also supports the two step model of E1A repression (Fig. 6) . The N-terminal repression domain of E1A appears capable of interacting with both the p300 E1A-binding domain and with TBP as a complex. The fact that the E1A N-terminus is capable of dissociating TBP from the TATA box provides functional significance to these proteinprotein interactions.
The two-step model predicts that (i) E1A can function to repress promoters containing bound p300, and that (ii) E1A can be found closely associated with chromatin. Preliminary evidence for both of these predictions has recently been found (Green and Loewenstein, manuscript in preparation) .
Materials and methods

Plasmids
pHIVLTR Tar+ used in the in vitro repression assay and pSV40 (p1-11) and pEGFP-N1 used in the in vivo repression assay were previously described (Boyd et al., 2002) . Glutathione S-transferase tagged TBP (GST-TBP) and the E1A-binding region of p300 (GST-p300 segment B′) were derived from pGEX vectors (Boyd et al., 2002) . phTBP was obtained from the laboratory of A. Berk.
Construction of plasmids expressing E1A 1-80 mutants
Construction of pQE12-E1A 1-80, pQE12-E1A 1-80Δ4-25 and pQE12-E1A 1-80Δ48-60 has been described (Song et al., 1995c) . Single amino acid substitution mutants were created in pQE12-E1A 1-80 using a Gene Tailor Site-Directed Mutagenesis System kit (Invitrogen). Briefly, the template pQE12-E1A 1-80 was treated with DNA methylase. PCR amplification was performed using the circular methylated template with two partially overlapping primers, both of which contained the target mutation. The linear double-stranded DNA product was transformed into DH5α-T1 bacterial cells in which the PCR product was circularized and the methylated template digested by endogenous McrBC endonuclease. Colonies remaining after antibiotic selection contained only unmethylated, mutated plasmid. In this manner, each amino acid in E1A 1-80 between residues 48 to 60 was, in turn, substituted with alanine except for 53Ala which was substituted with glycine. The sequence of each E1A 1-80 mutant was confirmed by DNA sequence analysis. After site-directed mutagenesis, the E1A 1-80 mutants were transferred from pQE12 into pQE70 (Qiagen) by PCR cloning. Each E1A 1-80 sequence was reconfirmed by DNA sequence analysis and transfected into M15/pRep4 bacterial cells (Qiagen).
His-tagged E1A 1-80 polypeptides, His-tagged hTBP, and GST fusion proteins E1A 1-80 polypeptides were prepared by a protocol described previously in detail (Boyd et al., 2002) . To prepare biologically active E1A 1-80 polypeptides, it is important to remove guanidine-HCl slowly as described (Boyd et al., 2002) . GST-TBP and a fusion of GST and the E1A-binding site containing B fragment of p300 (GST-p300 segment B′) were purified as described (Boyd et al., 2002) . hTBP was prepared essentially as described in Bryant et al. (1996) .
In vitro transcription repression assay
Preparation of nuclear transcription extracts and in vitro transcription repression assays were performed as described previously Boyd et al., 2002) .
Cell microinjection assay for transcription repression
Cell microinjection was performed by coinjection of E1A 1-80 mutant polypeptides with the E1A repressible promoter p1-11 which expresses the SV40 T antigen, essentially as described previously Boyd et al., 2002) . Briefly, A549 cells grown on cover slips were comicroinjected in the nucleus with p1-11 (8 ng/μl), the green fluorescent protein (GFP) producing plasmid pEGFP-N1 (10 ng/μl), and E1A 1-80 or E1A 1-80 mutant polypeptide (25 ng/μl). The level of p1-11 was titered so that ∼80% of successfully injected cells produce detectable T antigen by 4 h after injection. After fixation and permeabilization, cells were stained with mouse primary antibody against SV40 T antigen and with Texas Red conjugated goat anti-mouse secondary antibody. Successively injected cells produce GFP and were identified by fluorescence microscopy with a FITC filter. Successfully injected cells were scored for the production of T antigen by microscopic examination using fluorescence microscopy with a rhodamine filter. The data summarized in Fig. 4B represent the average of at least 3 independent experiments in which approximately 100 cells were injected for each E1A polypeptide.
Protein-binding assay
GST-linked agarose beads estimated to contain 150 ng of the GST-ligand (p300 E1A-binding site segment B′ or TBP) were preincubated for 1 h at 4°C with 500 μl of NP-40 buffer (40 mM HEPES pH 7.5, 150 mM KCl, 0. 5 mM EDTA, 1 mM DTT, 1 mM PMFS, 0.2% NP-40 supplemented with 0. 5 mg/ml of protein extract (sonicated and clarified M15/pRep4 bacterial cells). Preincubated beads were recovered by centrifugation at 250 × g for 1 min and resuspended in NP-40-binding buffer containing 75 ng of E1A 1-80 or E1A 1-80 mutant polypeptide (∼2-to 3-fold molar excess). E1A 1-80 or E1A 1-80 mutant polypeptides were incubated with the GST-ligand beads for 1 h at 4°C, and the beads were then recovered by centrifugation as before. Beads were washed in NP-40 buffer (without bacterial extract) supplemented with KCl to a final concentration of 250 mM. Bound proteins were eluted in SDS sample buffer, resolved by SDS PAGE on 12% polyacrylamide gels, transferred to PVDF membranes, and subjected to immunoblot analysis with affinity purified rabbit antibody directed against a CR1 peptide (E1A residues 40-80). Following incubation with secondary antibody (alkaline phosphatase linked mouse antirabbit antibody), the blots were treated with ECF reagent (Pharmacia-Amersham Biotech) and E1A 1-80 polypeptides quantitated by fluorescence laser scanning on a STORM 840 Phosphor-Imager using ImageQuant software (Molecular Dynamics).
TBP recruitment assay
GST and GST-p300 segment B′ calculated to contain 166 ng of ligand were preincubated as above in NP-40 buffer containing bacterial extract. After washing twice with NP-40 buffer without bacterial extract the beads were incubated at 4°C for 2 h in NP-40 buffer containing either no E1A 1-80 peptide or 1:0.5, 1:1, 1:2, 1:5, or 1:20 molar ratios of E1A 1-80. After washing the beads three times in NP-40 buffer, 350 ng (about a 2-fold molar excess) of hTBP was incubated with each resin aliquot overnight at 4°C in NP-40 buffer. Beads were washed three times in NP-40 buffer, and bound proteins were eluted in SDS sample buffer, resolved by SDS PAGE on 4-12% polyacrylamide gels, transferred to nitrocellulose membranes, and subjected to immunoblot analysis with affinity purified rabbit antibody directed against hTBP or to E1A. Following incubation with secondary antibody (horseradish peroxidase linked goat anti-rabbit), the blots were treated with a sensitive ECL reagent (SuperSignal West Femto Maximum Sensitivity Substrate; Pierce) and exposed to film.
Electrophoretic mobility shift analysis (EMSA)
GST-TBP was obtained from Santa Cruz. TFIID consensus oligonucleotide (Santa Cruz) was end-labeled with [
32 P] γ-ATP using polynucleotide kinase. Gel shift reactions were performed essentially as described previously (Boyd et al., 2002; Bryant et al., 1996; Tang et al., 1996) .
